Lifecare ASA: Mandatory notification of trade - allocation of Underwriting Commission Shares and Warrants

29 Jan 2026 14:45 CET

Reference is made to the stock exchange announcement published by Lifecare ASA
(the "Company") on 22 January 2026 and previous announcements regarding the
partially underwritten rights issue of new shares in the Company (the "Rights
Issue").

In connection with the Rights Issue, a total of 12,000,000 new shares (the
"Underwriting Commission Shares") shall be issued to the underwriters of the
Rights Issue, at a subscription price of NOK 0.50 per share (being the same
subscription price as in the Rights Issue), as settlement of their entitlement
to underwriting commission pursuant to the underwriting agreements dated 21
October 2025 entered into between the Company and the underwriters.

In accordance with the board authorisation granted by the extraordinary
general meeting held on 2 January 2026, the board of directors has today
resolved to increase the share capital of the Company with NOK 1,200,000
through the issuance of 12,000,000 Underwriting Commission Shares, each with a
par value of NOK 0.10, at a subscription price of NOK 0.50 per share.

Underwriters who subscribe Underwriting Commission Shares as settlement of the
underwriting commission shall receive warrants in two series: (i) three (3)
warrants for every four (4) Underwriting Commission Shares subscribed by the
underwriter, which will be exercisable in the exercise period from 2 March
2026 to 13 March 2026 ("Warrants Series 1"); and (ii) three (3) warrants for
every four (4) Underwriting Commission Shares subscribed by the underwriter,
which will be exercisable in the exercise period from 1 June 2026 to 12 June
2026 ("Warrants Series 2" and together with Warrants Series 1, the
"Warrants"). Consequently, in total 18,000,000 Warrants (9,000,000 Warrants
Series 1 and 9,000,000 Warrants Series 2) will be issued based on the number
of Underwriting Commission Shares to be issued to the underwriters.

Following the allocation, Hans Hekland, board member of the Company, has been
allocated in total 120,000 Underwriting Commission Shares and 180,000
Warrants.

Please see the attached PDMR form for further details.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-01-29 14:45 CET.

More information:
Access the news on Oslo Bors NewsWeb site

664460_Lifecare ASA- Mandatory notification of trade - allocation of Underwriting Commission Shares and Warrants.pdf
664460_260129 PDMR Attachment Hekland.pdf